Melanoma is the fifth most commonly diagnosed cancer in the U.S. Before 2011, treatment options for individuals diagnosed with advanced melanoma were limited with a five-year overall survival rate of approximately 10%. Since 2011, significant progress has been made with FDA approval of nearly 20 treatment options resulting in a five-year overall survival rate of more than 50%. This presentation will focus on recent updates for treating advanced melanoma.
Learning Objectives:
At the conclusion of this session, participants should be able to:
Describe the role of neoadjuvant therapy in resectable clinical stage III and oligometastatic stage IV melanoma
Summarize the data regarding sequencing of immunotherapy and targeted therapy in
BRAFV600E/K mutated advanced melanoma
Explain the evolving landscape in treatment of metastatic melanoma
.jpg "Heather Montane, PA, MS, RD (she/her/hers) photo")